Italia markets closed

Dow Jones
39.151,65
+39,49(+0,10%)
Nasdaq
17.740,15
+22,49(+0,13%)
Nikkei 225
39.667,07
+493,92(+1,26%)
EUR/USD
1,0680
-0,0035(-0,33%)
Bitcoin EUR
56.933,62
-1.363,45(-2,34%)
CMC Crypto 200
1.266,74
-17,05(-1,33%)

NBIX Dec 2024 195.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

3,2500

0,0000

(0,00%)

In data: 03:13PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat